Kurtis Holmes, DO
Family Medicine · Fruita, CONPI 1750464632
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $54,320 of the $55,986 with a category attached, or 97.0%. CSL Behring accounts for 84.2% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2020 at $14,488 and has fallen 99.4% since, to $84 in 2025. Among family medicine clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 204 payments — averaging $274.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$47K
- CSL Plasma Inc.$7K
- AbbVie$282
- GSK$208
- AstraZeneca$206
- Astellas Pharma US Inc$117
- plus $851 from 21 others
What the payments were for
- Consulting fees$54,32097%
- Food & beverage$1,6663%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 84 | $47,140 |
| CSL Plasma Inc. | 19 | $7,180 |
| AbbVie(2 entities) | 19 | $282 |
| GSK | 11 | $208 |
| AstraZeneca | 13 | $206 |
| Astellas Pharma US Inc | 7 | $117 |
| Pfizer | 8 | $116 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $112 |
| Biohaven Pharmaceuticals, Inc. | 5 | $97 |
| Johnson & Johnson | 6 | $90 |
| Amgen | 5 | $83 |
| Lilly USA, LLC | 4 | $57 |
| Novo Nordisk | 3 | $42 |
| Brainsway USA Inc | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Neurelis, Inc. | 1 | $24 |
| Dexcom, Inc. | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Edwards Lifesciences | 1 | $19 |
| Nestle Healthcare Nutrition Inc. | 1 | $17 |
| Seqirus USA Inc | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $14 |
| Avanir Pharmaceuticals, Inc. | 1 | $14 |
| Radius Health, Inc. | 1 | $13 |
| Pacira Therapeutics, Inc. | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
How this compares
$55,986 in reported general payments places this provider in the 95th percentile of 2,079 family medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 100 | $114,666 |
| OzempicSemaglutide | 38 | $47,398 |
| TrulicityDulaglutide | 19 | $25,947 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $21,577 |
| JardianceEmpagliflozin | 15 | $17,955 |
| Xtampza ErOxycodone Myristate | 14 | $11,720 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $6,789 |
| Pregabalin | 50 | $6,740 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $6,055 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 118 | $4,428 |
| Levothyroxine Sodium | 310 | $3,210 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 97 | $2,613 |
| Gabapentin | 96 | $2,441 |
| Atorvastatin Calcium | 450 | $2,409 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $2,393 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $116 | $114,666100 claims |
| Novo NordiskOzempic | $42 | $47,39838 claims |
| Lilly USA, LLCTrulicity | $57 | $25,94719 claims |
| GSKTrelegy Ellipta | $208 | $21,57721 claims |
| AstraZenecaSymbicort | $206 | $6,05516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,079 family medicine providers in Colorado.
Other family medicine in Fruita
- Vanessa McClellanFruita$16K
- Ethan LazarusDenver$688K
- Michael de NardisLarkspur$335K
- Matthew YoungColorado Springs$270K
- Mark DeutchmanDenver$258K
- Kari UusinarkausWoodland Park$254K
- Michael MeekerUsaf Academy$174K
- Carolynn Francavilla BrownLakewood$174K
- Lawrence AndrewsColorado Springs$102K
- Gregory MaederWestminster$95K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.